In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutraceutix

Division of Probi AB
www.nutraceutix.com

Latest From Nutraceutix

RedHill nears NDA for its version of GSK's Zofran

RedHill Biopharma has said it intends "to request a pre-NDA meeting with the FDA in the coming weeks to discuss a US NDA marketing approval application for RHB-102", its once-daily controlled release formulation of the antiemetic, ondansetron, for the prevention of nausea and vomiting in cancer patients.

Gastrointestinal Cancer

New Products In Brief

GOGO reformulates Purell sanitizer; Life Extension brews up glucose support supplement; AllergEase allergy lozenges out in time for spring; Cardia 7 claims “heartier omega” mantle; extended-release SCOLR supplements debut; Tom’s of Maine rolls out natural antiperspirant; more New Products In Brief.

Consumer Launches

New Products In Brief

GOGO reformulates Purell sanitizer; Life Extension brews up glucose support supplement; AllergEase allergy lozenges out in time for spring; Cardia 7 claims “heartier omega” mantle; extended-release SCOLR supplements debut; Tom’s of Maine rolls out natural antiperspirant; more New Products In Brief.

Consumer Launches

Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Scolr Pharma Inc.
  • Scolr Inc.
  • Nutraceutix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Probi AB
  • Senior Management
  • Stephen Turner, Pres. & CEO
    Richard M Levy, CFO & VP, Fin.
  • Contact Info
  • Nutraceutix
    Phone: (425) 883-9518
    9609 153rd Ave. NE
    Redmond, WA 98052
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register